Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.45 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22645885 | 1.00 | LMNA (0.48) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| SCHEMBL18641655 | 1.00 | LMNA (0.48) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| SCHEMBL27415189 | 0.99 | LMNA (0.47) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| SCHEMBL25531486 | 0.95 | LMNA (0.50) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| SCHEMBL25528219 | 0.95 | LMNA (0.50) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| SCHEMBL27388656 | 0.94 | LMNA (0.49) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| SCHEMBL25067341 | 0.92 | PRKCA (0.50) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| SCHEMBL18665302 | 0.92 | PRKCA (0.50) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| SCHEMBL22645880 | 0.92 | PRKCA (0.50) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| SCHEMBL27415249 | 0.92 | MAPK1 (0.49) | LMNAALDH1A1PRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | LMNA 2139/4885ALDH1A1 3662/4885PRKCA 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.